Prevalence of Blastocystis infection in patients with colorectal cancer in Taiwan Authors: Chen-Chieh Liao, Chun-Hsien Chen, Chih-Ming Tsai, Pok-Man Cheang, Wei-Chen Lin, Po-Chuan Chen, Chien-Chin Chen, Chun-Ting Chu Published: 2025 ABSTRACT AbstractBlastocystis sp., an understudied intestinal protozoan associated with gastrointestinal symptoms, has an unclear role in the pathogenesis of colorectal cancer (CRC). Despite available international data, the epidemiology of Blastocystis infection in Taiwanese CRC patients has not been established. In this study, we investigated its prevalence by analyzing samples from 56 CRC patients at National Cheng Kung University Hospital from August 2021 to July 2022. The cohort consisted of 32 males (57.1%) and 24 females (42.9%) with a mean age of 62.2 ± 10.4 years. We found the overall prevalence of Blastocystis sp. to be 28.6%, with males exhibiting a higher rate. Notably, the infection was detected across all stages and grades of CRC within our study group.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-025-12177-7.Keywords: Blastocystis sp., Colorectal cancer, Parasite, Tumorigenesis, Tumor microenvironment Introduction Blastocystis sp. is a protozoan commonly found in human feces and is widespread in rural and urban settings. It has been linked to various gastrointestinal (GI) symptoms, including diarrhea, abdominal pain, and bloating. Research interest in exploring the potential correlation between Blastocystis sp. and colorectal cancer (CRC) has recently increased [1]. Previously, Blastocystis has been shown to exacerbate CRC by modulating the murine immune response and increasing oxidative damage [2]. Another hypothesis suggests that Blastocystis might interact with intestinal bacteria during the development of CRC [3]. A recent report released by the Health Promotion Administration ranked CRC as the most common cancer in Taiwan [4]. CRC affects the colon or rectum in the large intestine and is a major global health concern, responsible for a significant number of cancer-related deaths worldwide [5]. Typically, slow-developing, CRC arises from non-cancerous polyps in the colon or rectum, which can become cancerous and spread if left untreated. Its symptoms include changes in bowel habits, bloody stools, abdominal pain or discomfort, and unexplained weight loss [5]. The tumor microenvironment in CRC is complex, comprising metabolic factors, cancer and immune cells, and intestinal microorganisms [6]. While the exact causes of CRC are poorly understood, several risk factors have been identified, including age, family history of CRC, inflammatory bowel disease (IBD), certain genetic mutations, and lifestyle factors, such as poor diet and physical inactivity [7]. The gut microbiota of patients with CRC differs from that of healthy individuals. Fusobacterium nucleatum, Escherichia coli, and Bacteroides fragilis are the most significant species associated with CRC development [6]. Intestinal colonization by Blastocystis sp. has been linked to colorectal cancer (CRC) in studies from other areas, where it is sometimes considered a potential risk factor [1]. Blastocystis sp. infection can potentially alter gut microbiota composition, leading to GI diseases, including CRC [8, 9]. However, the precise role of Blastocystis in CRC development remains unclear. Notably, while international data exists, no epidemiological study has characterized the prevalence of Blastocystis infection among CRC patients in Taiwan. Therefore, our study aimed to determine the prevalence of genetically identified Blastocystis infections in a cohort of Taiwanese CRC patients. To our knowledge, this is the first report to describe these epidemiological features within this specific population in Taiwan. Methods and results This study was conducted from August 2021 to July 2022 and included patients of both sexes and all ages diagnosed with CRC (n = 56) at the National Cheng Kung University Hospital (NCKUH) and was approved by the Institutional Review Board (B-BR-109-114) at NCKUH. All collected fecal samples were utilized for the detection of Blastocystis sp., using PCR. The collection process of fecal specimens involved the use of clean DNA/RNA Shield fecal collection tubes (Zymo Research, USA). Each container was labeled appropriately with the date of collection, patient’s name, and a unique serial number. These samples were stored in 4 °C. In this study, we analyzed samples from 56 patients with CRC whose ages ranged from 41 to 84 years, with a mean age of 62.22 ± 10.38 years. Among the participants, 57.1% (32/56 cases) were male, and 42.9% (24/56 cases) were female (Table 1). The pathologic and clinical staging of these patients diagnosed with CRC ranged from 0 to IV, respectively. The distribution across clinical and pathological staging showed that clinical and pathological stage III were predominant, at 48.2% (27 out of 56 cases) and 37.5% (21 out of 56 cases), respectively (Table 1). Among male patients, 59.4% were classified as clinical stage III, representing the highest proportion across all stages. Among female patients, 41.7% were classified as pathologic stage III, which was the highest proportion within that group. However, there was no statistically significant association was found between Blastocystis infection and gender, clinical stage, or pathological grade. Table 1Clinical staging and pathological grading in colorectal cancer patientsStage0IIIIIIIVTotal2 (3.6)11 (19.6)10 (17.9)27 (48.2)6 (10.7)56Male (%)1 (3.1)4 (12.5)6 (18.8)19 (59.4)3 (9.4)32Female (%)1 (4.2)7 (20.8)4 (16.7)8 (33.3)3 (12.5)24 Grade 0 I II III IV Total8 (14.3)11 (19.6)13 (23.2)21 (37.5)4 (5.4)56Male (%)3 (9.4)8 (25.0)8 (25.0)11 (19.6)2 (6.3)32Female (%)5 (20.8)3 (12.5)5 (20.8)10 (41.7)1 (4.2)24 Clinical staging and pathological grading in colorectal cancer patients Genomic DNA was extracted from the fecal samples using the ZymoBIOMICS DNA Miniprep Kit (D4300, Zymo Research, USA). Detection of a partial small subunit ribosomal ribonucleic acid (SSU rRNA) sequence (310 bp) was performed using the primer pair bl1400ForC (5’-GGA ATC CTC TTA GAG GGA CAC TAT ACA T-3’) and bl1710RevC (5’-TTA CTA AAA TCC AAA GTG TTC ATC GGA C-3’) (Fig. 1) [10]. The analysis revealed an overall Blastocystis prevalence of 28.6% (16/56 cases), with a higher rate in males (34.4%) than in females (20.8%) (Table 2). The association between parasite prevalence and categorical variables (sex, stage and grade) was assessed using Fisher’s exact test. Statistical significance was set at $p < 0.05. PCR-based detection of Blastocystis sp. in the fecal samples collected from CRC patients. PCR amplification was performed using bl1400ForC/bl1710RevC primers set, targeting a 310 bp fragment. The PCR products were separated using 1% agarose gels and photographed. PCR products stained with DNA-view were separated on a 1% agarose gel using electrophoresis (DNA-view, BIOTOOLS Co. Ltd, Taiwan). Lane +: Positive control; Lane -: Negative control; Lane 1–9: Genomic DNA extracted from fecal samples of CRC patients Table 2Prevalence of Blastocystis sp. infection in patients with colorectal cancerB.hominis-positivep-value Number/total (%) 16/56 (28.6) Sex Male11/32 (34.4)0.36Female5/24 (20.8) Stage 0/I/II5/23 (21.7)0.38III/IV11/33 (33.3) Grade 0/I/II11/33 (33.3)0.38III/IV5/23 (21.7) Prevalence of Blastocystis sp. infection in patients with colorectal cancer Discussion Blastocystis is an intestinal protozoan parasite commonly found in humans and several other animals. Previous studies reported that the prevalence of Blastocystis sp. ranges from 1.13% in healthy individuals to 11%–18% in foreign laborers in Taiwan [11, 12]. The prevalence of Blastocystis sp. ranges from 1.6% to 16% in developed areas such as China’s mainland, Singapore, and Japan [13–15]. Recent studies have suggested an association between Blastocystis sp. infection and CRC and have shown that Blastocystis infection can potentially exacerbate existing CRC by altering the immune response of the host and increasing oxidative damage [1, 16]. Chronic Blastocystis sp. infections have also been linked to various pathophysiological disorders and mutations, which result in prolonged oxidative stress that can promote cancer development [17]. Another study suggests that while Blastocystis may not directly induce tumorigenesis in colonic tissues, it could exacerbate the progression of pre-existing colorectal tumors in vitro [18]. Additionally, the Blastocystis sp. solubilized antigen was shown to promote the growth of human CRC cells, specifically HCT116 cells [19]. The observed prevalence of Blastocystis sp. infection in our CRC patients was 28.6%. However, this figure must be interpreted with caution. As our study lacked a matched healthy control group, it is difficult to accurately assess whether this prevalence is significantly higher than that of the general healthy population in Taiwan [20, 21]. The primary limitation of this study is its small sample size (n = 56), which may reduce statistical power and limit the generalizability of the findings. Nevertheless, the observed trend provides preliminary insight into the potential association between Blastocystis sp. infection and colorectal cancer, which positions this study as a preliminary exploration for large-scale multicenter case-control studies. Conclusions In summary, the role of Blastocystis sp. infection in the development of CRC and its interaction with tumor-associated gut microbiota in patients with CRC remains unclear. This study provides the first epidemiological data on Blastocystis infection among patients with CRC in Taiwan, identifying a prevalence of 28.6%. Moreover, Blastocystis infection rates were found to be higher in patients with clinical stages III and IV. Our findings indicate that Blastocystis infection is relatively common in CRC patients in Taiwan (28.6%) and may be more frequent in advanced stages. While these findings suggest a potential association, further case-control and mechanistic studies are required to clarify whether Blastocystis contributes to CRC development or progression. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements Not applicable. Abbreviations Colorectal cancer Inflammatory bowel disease Author contributions The co-first author, Chen-Chieh Liao, designed and conducted the major experiments. The co-first author, Chun-Hsien Chen, was a major contributor to writing the manuscript. Chih-Ming Tsai contributed to the manuscript’s modification and English writing. Pok-Man Cheang conducted the DNA extraction of fecal samples. Wei-Chen Lin made substantial contributions to the conception. Po-Chuan Chen conducted the collection of clinical samples. Chien-Chin Chen provided the statistical analysis and the funding. Chun-Ting Chu made substantial contributions to the conception. Funding This work was supported by research grants from the Ditmanson Medical Foundation Chia-Yi Christian Hospital and National Cheng Kung University Hospital (NCKUCYC-P-11102-1). Data availability All data generated or analyzed during this study are included in this published article. Declarations Ethics approval and consent to participate This study was approved by the Institutional Review Board of National Cheng Kung University Hospital (IRB No.: B-Br-109-114) in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants before the collection of their samples. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Chen-Chieh Liao and Chun-Hsien Chen contributed equally to this work. Contributor Information Chien-Chin Chen, Email: hlmarkc@gmail.com. Chun-Ting Chu, Email: gustochu@gmail.com. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement All data generated or analyzed during this study are included in this published article.